Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of mivelsiran in adults aged 40 to 55 years who have early-stage Down Syndrome-Associated Alzheimers Disease DS-AD. This Phase 2 study focuses on understanding the safety, tolerability, and pharmacodynamics of intrathecally administered mivelsiran. The study is sponsored by Alnylam Pharmaceuticals and involves a randomized, placebo-controlled design with quadruple masking to ensure unbiased results. Participants will receive multiple doses of either low or high amounts of mivelsiran, or a placebo, administered directly into the spinal canal. The study includes two main periods a 24-month double-blind phase where neither participants nor researchers know the group assignments, followed by an optional 12-month open-label extension where all participants may receive mivelsiran. This approach allows thorough assessment of the treatment effects over an extended timeframe. During the study, participants will undergo evaluations of brain amyloid burden using imaging, along with measurements of relevant proteins in cerebrospinal fluid and plasma. Cognitive function will also be monitored. Safety assessments include tracking adverse events throughout both the double-blind and extension periods. Overall participation may last up to 39 months, including screening, treatment, and safety follow-up to ensure comprehensive data collection on the interventions impact.
Actively Recruiting
Neck pain often occurs alongside conditions affecting organs near the diaphragm, which share nerve connections through the phrenic nerve. This trial evaluates whether blocking the phrenic nerve can reduce sensitivity and improve neck pain symptoms in people without neurological, traumatic, or infectious causes of pain. The study is a randomized controlled trial aiming to better understand the role of visceral organ involvement in neck pain and to identify potential targeted treatments. Participants will be randomly assigned to one of two groups. The experimental group will receive an ultrasound-guided injection of local anesthetics lidocaine and bupivacaine around the phrenic nerve to block nerve signals. The control group will receive a similar procedure with a saline solution as a placebo. The intervention involves a single session with follow-up assessments over one week to monitor changes. During the study, participants will undergo several evaluations including pain threshold measurements using algometry, range of motion tests, visual pain scales, and neck disability questionnaires. These assessments will be done before the procedure and at multiple points up to seven days afterward. The researchers will track changes in pain sensitivity and functional outcomes to determine the effects of phrenic nerve blockade on neck pain.